Pazopanib in advanced soft tissue sarcomas.

Signal Transduct Target Ther · 2019 · PMC6522548 · PMID 31123606

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In contrast, in a smaller study of 25 patients treated with pazopanib in several Japanese centers, a decrease in NLR from baseline to Week 4 of therapy showed a highly significant association with improved PFS, while baseline NLR had no prognostic association 64 .

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.